Shoutai Pill (寿胎丸) attenuates maternal-fetal interface inflammation by inhibiting NLRP3-mediated trophoblast pyroptosis

Read full text Summarise with VIRAT
Authors: Yingqing CHEN, Ali Deng, Mengxin XIONG, Haoxue ZHANG, Zeyu JIANG
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

目的 探讨寿胎丸对复发性流产(RSA)小鼠的治疗效果及其对NOD样受体蛋白3(NLRP3)炎症小体的影响,阐明其调节滋养细胞焦亡的机制。 方法 采用Clark经典CBA/J×DBA/2作为RSA模型,将其随机分为模型组、地屈孕酮组、寿胎丸低剂量组、寿胎丸高剂量组;CBA/J×BALB/C为正常妊娠模型,作为对照组;每组10只,分别予药物治疗14天。观察各组孕鼠胚胎吸收率;苏木素-伊红(HE)染色观察胎盘组织病理形态、炎症反应程度;酶联免疫吸附试验(ELISA)检测小鼠血清白介素(IL)-1β、IL-18含量;蛋白免疫印迹(Western blot)检测胎盘组织与NLRP3炎症小体活化相关NLRP3、胱天蛋白酶(Caspase)-1、消皮素D (GSDMD)、IL-1β、IL-18蛋白的表达水平;免疫组织化学技术(IHC)检测胎盘组织NLRP3、Caspase-1的表达;免疫荧光技术(IF)检测胎盘组织NLRP3炎症小体关键蛋白NLRP3在滋养细胞的共表达情况。 结果 与对照组比较,模型组孕鼠胚胎吸收率明显增加(P

Fields of Study & Subjects

Reproductive System and Pregnancy Inflammasome and immune disorders Pregnancy and preeclampsia studies

Publication details

Journal / source
Lishizhen Medicine and Materia Medica Research
Volume
37
Issue
5
Pages
821–828
Publication date
1 March 2026
Language
EN